profits news from FiercePharma
News
Could Clarinex be vulnerable to generics?
Consider this scenario from Fred Hassan's nightmares: The $800 million Clarinex, ostensibly under patent till 2020, Read more...
Novartis restricts Zelnorm to emergencies
Goodbye cruel world. Novartis is pulling the irritable bowel med Zelnorm off the market almost completely, saying it will supply the drug only for emergency use. And even in emergencies, Zelnorm will Read more...
FTC sues Cephalon for blocking generics
Here's one way generics might pay off. The feds are accusing Cephalon of bribing drugmakers to keep copycat Provigil off the market. According to an FTC lawsuit against the company, Cephalon paid Read more...
Earnings from Schering, Sanofi, Teva
It's an earnings kind of day today, with two of the brand-name biggies reporting, plus the leading generics maker. Here are the results:Schering-Plough reported a $3.4 billion loss for the fourth Read more...
Merck joins Fosamax copycats
Merck won't be outdone on Fosamax. The company has struck a deal with an unidentified generics supplier for an authorized, copycat form of the osteoporosis drug. The Merck-blessed generic could go on Read more...
Revlimid fuels Celgene sales rocket
Here's what one big drug can do: Celgene announced that it expects fiscal 2007 profits to double to $1.05 per share, as sales of its cancer drug Read more...
ALSO NOTED: Merck vaccine prevents cervical cancer in older women; Diabetes sales drive 37 percent increase in Takeda profits;
> Gardasil protects against cervical cancer in women as old as 45, a new study shows; previously, the vaccine was only proven to work in women ages 9 to 26. Read more...
AZ hit with Crestor patent challenge
It's a one-two punch for AstraZeneca today. A Canadian drug maker is challenging AZ's patent on the cholesterol drug Crestor, one of its top sellers at $2 billion--and a linchpin of its profits over Read more...
It's Barr v. Watson in Estrostep face-off
Here's how winning a patent fight could become a setback. The drug in question: Estrostep Fe, the contraceptive pill made by Warner Chilcott. In 2004, Warner agreed to let generics maker Barr Read more...
Schering stock falls on profits
Schering-Plough posted strong profits and double-digit sales growth yesterday--but its stock plunged. So what gives? Well, it's true that the drug maker doubled profits only on one-time gains; Read more...
Get more profits coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight